A long-term study of photodynamic therapy with verteporfin for choroidal neovascularization at the edge of chorioretinal atrophy in pathologic myopia

Alfredo Pece, Paolo Milani, Vincenzo Isola, Luisa Pierro

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the effects of verteporfin photodynamic therapy (PDT) on choroidal neovascularization (CNV) at the edge of chorioretinal atrophy in eyes with pathologic myopia. Procedures: Twenty eyes of 20 consecutive patients were treated according to Verteporfin in Photodynamic Therapy criteria. The patients were divided into 3 groups based on CNV location and were followed up with clinical and fluorescein angiographic examinations to evaluate visual acuity (VA) changes and number of treatments. Results: The mean follow-up was 35 months. In group 1 (n = 8; subfoveal CNV), VA declined from 20/73 (0.56 ± 0.26 logMAR) to 20/115 (0.76 ± 0.30 logMAR; p = 0.192). In group 2 (n = 6; juxtafoveal CNV), VA improved from 20/69 (0.54 ± 0.25 logMAR) to 20/46 (0.36 ± 0.16 logMAR; p = 0.176). In group 3 (n = 6; extrafoveal CNV), VA worsened from 20/50 (0.40 ± 0.21 logMAR) to 20/91 (0.66 ± 0.49 logMAR; p = 0.292). Conclusions: PDT showed inhibitory effects on myopic CNV arising at the edge of chorioretinal atrophy, especially in young adult myopic eyes with juxtafoveal neovascular membranes.

Original languageEnglish
Pages (from-to)161-168
Number of pages8
JournalOphthalmologica
Volume225
Issue number3
DOIs
Publication statusPublished - Mar 2011

Keywords

  • Chorioretinal atrophy
  • Choroidal neovascularization
  • Pathologic myopia
  • Photodynamic therapy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Fingerprint Dive into the research topics of 'A long-term study of photodynamic therapy with verteporfin for choroidal neovascularization at the edge of chorioretinal atrophy in pathologic myopia'. Together they form a unique fingerprint.

  • Cite this